Mazdutide

Overview

Mazdutide, known by the development code IBI362, is an investigational peptide being studied primarily for obesity and related metabolic conditions. It belongs to the same emerging category of dual-acting metabolic therapies as several other next-generation candidates, and it is important to state clearly that mazdutide is not an approved drug in most markets and remains under clinical investigation.

Mazdutide is described as an oxyntomodulin analog, meaning it is modeled on a naturally occurring gut hormone that engages more than one receptor. Specifically, it acts on both the GLP-1 and glucagon receptors, placing it in the dual-agonist class designed to combine appetite suppression with effects on energy expenditure. This design reflects the broader strategy of targeting multiple metabolic pathways at once to enhance weight-related outcomes.

The program has advanced notably in China, where development has moved through later-stage clinical evaluation. Its progress there has drawn attention as part of a globalizing landscape of metabolic drug development. As with all investigational peptides, the appropriate framing is cautious: encouraging clinical progress is not the same as established safety and efficacy, and approval status varies by region.

How it works

Mazdutide is built on the structure of oxyntomodulin, a naturally occurring hormone released from the gut after eating that simultaneously stimulates the GLP-1 and glucagon receptors. By mimicking this dual activity, mazdutide aims to harness both pathways in a single molecule, an approach intended to produce broader metabolic effects than targeting either receptor alone.

The GLP-1 arm contributes the familiar incretin effects: enhanced insulin secretion in response to food, slowed gastric emptying, and reduced appetite through action on brain centers governing hunger. This drives lower food intake and improved blood sugar handling. The glucagon arm is intended to increase energy expenditure and influence fat metabolism, adding a calorie-burning dimension that complements the appetite-reducing GLP-1 effect.

The central design rationale is that combining these complementary actions can deliver greater weight reduction than single-target therapies, while the glucagon component may also support improvements in liver fat and overall metabolic profile. As with all dual agonists, the practical challenge lies in balancing the two activities so that the glucagon-driven effects enhance fat metabolism without compromising the glucose benefits delivered by the GLP-1 component.

Research & evidence

Mazdutide has progressed through clinical studies, with development particularly advanced in China, where it has reached later-stage trials for obesity and related metabolic indications. Reported results have pointed toward effects on body weight consistent with the broader promise of dual GLP-1/glucagon agonists. This progress has positioned mazdutide as a notable candidate within the global metabolic drug pipeline.

Nonetheless, important caveats apply. Much of the most advanced clinical work is concentrated in specific regions, and broader international evidence and regulatory review are still developing. As with any investigational therapy, questions remain about long-term efficacy, durability of weight loss, and the full safety profile across diverse populations and extended treatment periods. Early and mid-stage results, however encouraging, do not guarantee that the therapy will ultimately prove both safe and effective at scale.

The honest assessment is that mazdutide is a promising investigational candidate that has made substantial clinical progress, especially in China, but that remains unproven in the fullest sense. Its eventual role, if any, in approved metabolic care will depend on the completion of comprehensive trials and regulatory evaluation across markets.

Safety & legal status

Mazdutide is an investigational drug and is not broadly approved, including by the FDA, for general use. Regulatory status differs by region, and its development has been most advanced in China; even where late-stage trials have occurred, this does not equate to worldwide availability or approval. Any product marketed outside legitimate medical and regulatory channels claiming to be mazdutide should be regarded with strong caution, as such material is unregulated and of unverified identity and purity.

The safety profile continues to be characterized through clinical studies. Drawing on the broader incretin and glucagon-agonist class, gastrointestinal effects such as nausea are commonly anticipated, and the glucagon component introduces additional metabolic considerations that trials are specifically designed to evaluate. Because comprehensive long-term safety data are still being gathered, no definitive risk conclusions can responsibly be stated.

This guide intentionally provides no dosing information, as mazdutide is an experimental compound appropriate only within supervised clinical research. People interested in treatments for obesity or metabolic conditions should discuss approved, evidence-based options with qualified healthcare professionals rather than seeking investigational peptides through unofficial sources.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Ji L, Gao L, Jiang H, et al. Safety and efficacy of the GLP-1/glucagon dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity: a phase 1b trial. eClinicalMedicine. 2022. Peer-reviewed study
2. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023. Peer-reviewed study
3. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. Peer-reviewed study
4. Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026. Peer-reviewed study
5. Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024. Peer-reviewed study
6. Shirley M. Mazdutide: First Approval. Drugs. 2025. Peer-reviewed study